Diseases of the Sexual Glands (Gonads) in Children

1. Rajesh Rishika

2. Bugubaeva Makhabat Mitalipovna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.

2. HOD Clinical Disciplines-2, Associate Professor, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic)

Abstract

The sexual glands, or gonads (testes in males and ovaries in females), are pivotal endocrine and reproductive organs whose function is intricately regulated by the hypothalamic-pituitary-gonadal (HPG) axis. Diseases affecting these glands during childhood and adolescence can profoundly disrupt the critical processes of sexual differentiation, pubertal development, and future fertility. This article presents a comprehensive, university-style analysis, structured in the IMRAD format, focusing on the major categories of gonadal disorders encountered in the pediatric population. The primary focus encompasses Disorders of Sex Development (DSD), including those due to defects in androgen synthesis or action; Gonadal Failure (Hypogonadism), both primary (hypergonadotropic) and secondary (hypogonadotropic); and Gonadal Tumors. A rigorous comparison of the molecular etiologies, clinical presentations, diagnostic challenges, and management strategies is provided. Understanding the genetic, hormonal, and developmental context of these diseases is crucial, as delayed or inaccurate diagnosis can lead to irreversible consequences for physical, psychological, and reproductive health. The unique complexity of gonadal pathology in children necessitates a multidisciplinary approach involving pediatric endocrinologists, geneticists, surgeons, and mental health specialists.

Introduction: The Central Role of Gonads in Pediatric Development

The gonads—the testes and ovaries—serve a dual, indispensable role: gametogenesis (production of sperm and ova) and steroidogenesis (production of sex steroids, primarily testosterone and estrogen). In the pediatric context, gonadal function is critical for two distinct phases: fetal sex differentiation and pubertal maturation. Disruptions during these periods lead to fundamentally different, yet equally impactful, clinical syndromes.

During the fetal period, the presence and function of the testes are essential for the male internal and external genital development, driven by Testosterone and Anti-Müllerian Hormone (AMH). Defects here result in Disorders of Sex Development (DSD), leading to atypical development of chromosomal, gonadal, or anatomical sex. Postnatally, the gonads are quiescent until the onset of puberty, a process reactivated by the hypothalamic GnRH pulse generator. The resultant rise in gonadal steroid production drives the development of secondary sexual characteristics, acquisition of peak bone mass, and eventual fertility.

Diseases of the gonads in children are broadly categorized based on the phase of development they impact and the resulting functional deficit: DSDs (affecting differentiation), Hypogonadism (affecting pubertal development and function), and Neoplasia (affecting structure and potentially function). The molecular etiologies are diverse, spanning chromosomal abnormalities (e.g., Klinefelter and Turner syndromes), monogenic defects affecting hormone synthesis or action, and acquired damage (e.g., trauma, infection, chemotherapy). Given the sensitive nature of these conditions, accurate, timely, and sensitive management is paramount. A comprehensive, academically rigorous exploration of these complex disorders is essential for advancing clinical practice in pediatric endocrinology and genetics.

Methods

The methodological foundation for this academic analysis involved a rigorous, systematic review of current, peer-reviewed scientific literature and established clinical guidelines concerning pediatric gonadal disorders. The aim was to synthesize complex genetic, endocrine, and clinical data into a cohesive, comparative narrative.

i. Search Strategy and Data Source Curation

A comprehensive literature search was executed across major medical databases, including PubMed, Web of Science, and guidelines from specialized societies (e.g., Endocrine Society, European Society for Paediatric Endocrinology). Key search terms utilized included: "Disorders of Sex Development (DSD) pediatric," "congenital hypogonadism in children," "Klinefelter syndrome testosterone replacement," "Turner syndrome ovarian failure," "pediatric gonadal tumors," and "steroidogenesis enzyme defects." The search prioritized contemporary articles published since the 2006 Consensus Statement on DSD nomenclature, focusing on recent advances in genetic diagnosis (e.g., next-generation sequencing) and long-term management protocols. Emphasis was placed on studies detailing genotype-phenotype correlations and the management of psychosocial aspects of DSD.

ii. Comparative Pathology Framework

A structured, three-point comparative framework was applied to organize and analyze the three major categories of pediatric gonadal pathology: Disorders of Sex Development (DSD), Primary Gonadal Failure (Hypogonadism), and Gonadal Neoplasia.

The comparison focused on the following key parameters:

1.     Etiology/Genetic Basis: Chromosomal abnormalities, single-gene mutations (e.g., SRY, steroidogenic enzymes), or acquired factors.

2.     Primary Pathophysiological Mechanism: Defect in differentiation (DSD), failure of steroidogenesis/gametogenesis (Hypogonadism), or uncontrolled proliferation (Neoplasia).

3.     Hormonal Profile & Management Goal: Specific deficiencies or excesses, and the principal therapeutic intervention (e.g., hormone replacement, suppression, surgical removal).

This systematic approach facilitated a detailed, comparative exposition of the distinct pathways through which gonadal function is compromised in children.

Results: Molecular Etiology, Differentiation Defects, and Functional Failure

The comprehensive review confirms that pediatric gonadal diseases manifest through three primary mechanisms: disrupted fetal differentiation (DSD), primary failure to maintain function postnatally (Hypogonadism), and neoplastic transformation. The molecular underpinnings of these categories are distinct and reveal specific genotype-phenotype correlations.

i. Disorders of Sex Development (DSD): Defects in Fetal Differentiation

DSDs are defined as congenital conditions where the development of chromosomal, gonadal, or anatomical sex is atypical. The classification system is based on the karyotype: 46, XY DSD, 46, XX DSD, and Sex Chromosome DSD (e.g., 45, X, 47, XXY).

i.a. 46, XY DSD: Testicular Differentiation Failure or Androgen Pathway Defects

In 46, XY DSD, the presence of a Y chromosome dictates testicular formation, but the subsequent steps of male differentiation fail. The defect can originate from:

1.     Impaired Testicular Development: Caused by mutations in genes involved in testis formation (e.g., SRY, SOX9, or DMRT1). This leads to conditions like Gonadal Dysgenesis, where the testes are rudimentary or streaked.

2.     Defective Androgen Synthesis: Mutations in steroidogenic enzymes, most commonly 17 α-hydroxylase (CYP17A1) or 17 β-hydroxysteroid dehydrogenase type 3 (HSD17B3), prevent the production of testosterone from its precursors.

3.     Defective Androgen Action: This includes Androgen Insensitivity Syndrome (AIS), caused by mutations in the Androgen Receptor (AR) gene. Complete AIS (CAIS) results in an external female phenotype despite normal male levels of testosterone and AMH (the latter leading to the absence of Müllerian structures).

The primary pathological outcome is the failure of Wolffian duct development and/or incomplete virilization of the external genitalia, leading to phenotypes ranging from complete female external appearance to varying degrees of ambiguous genitalia.

i.b. 46, XX DSD: Androgen Excess

46, XX DSD is most frequently caused by fetal androgen excess. The overwhelming majority of these cases are due to Congenital Adrenal Hyperplasia (CAH), specifically 21-hydroxylase deficiency (CYP21A2 gene mutation). This enzyme deficiency prevents cortisol synthesis, leading to high ACTH release, which drives the overproduction of adrenal androgens (e.g., androstenedione). These androgens virilize the external genitalia of the genetically female fetus, while the ovaries (developing autonomously) are structurally normal.

ii. Primary Gonadal Failure (Hypogonadism): Postnatal Functional Breakdown

Primary Hypogonadism (or Hypergonadotropic Hypogonadism) refers to gonadal dysfunction that occurs postnatally, characterized by failure to achieve or progress through puberty due to intrinsic gonadal damage, resulting in low sex steroids despite high pituitary gonadotropin (LH/FSH) stimulation.

ii.a. Sex Chromosome Aneuploidies

The most common genetic causes of primary hypogonadism are the sex chromosome aneuploidies:

·       Turner Syndrome (45, X in girls): The loss of the second X chromosome causes accelerated atresia of the primordial ovarian follicles, resulting in ovarian dysgenesis and near-complete loss of ovarian function by mid-childhood. The pathological findings show streak gonads, leading to primary amenorrhea and absence of secondary sexual characteristics.

·       Klinefelter Syndrome (47, XXY in boys): The supernumerary X chromosome causes progressive damage to the seminiferous tubules (leading to hypergonadotropic azoospermia) and, often, Leydig cell dysfunction (leading to low testosterone). The testes are typically small, firm, and fibrotic, and these individuals often experience delayed or incomplete puberty.

ii.b. Acquired Causes

Acquired causes contribute significantly and include testicular torsion, orchitis (e.g., post-mumps), gonadotoxic therapy (chemotherapy or radiation for childhood cancers), and autoimmune destruction. The pathophysiology involves direct cellular damage to the steroidogenic (Leydig/theca) or gametogenic (Sertoli/granulosa) compartments, resulting in irreversible fibrosis and functional impairment.

iii. Gonadal Neoplasia: Structural and Hormonal Disruption

Gonadal tumors, though rare in childhood, represent a critical area of pathology due to their potential for malignancy and the acute disruption of hormone production.

·       Testicular Tumors: In pre-pubertal boys, Yolk Sac Tumors are the most common malignant germ cell tumor. Leydig Cell Tumors are the most common sex cord-stromal tumors and are particularly notable because they are often hormonally active, causing gonadotropin-independent precocious puberty (excess testosterone production, suppressing LH/FSH).

·       Ovarian Tumors: Ovarian tumors are more common than testicular tumors in girls. Germ Cell Tumors (e.g., teratomas) are most frequent, followed by Sex Cord-Stromal Tumors (e.g., Granulosa Cell Tumors). The juvenile type of Granulosa Cell Tumor is often estrogen-secreting, causing peripheral precocious puberty (precocious thelarche and menstrual bleeding without hypothalamic-pituitary activation). The pathophysiology involves autonomous steroidogenesis, bypassing the regulatory control of the HPG axis.

Discussion: Diagnosis, Psychosocial Burden, and Long-Term Management

The results establish that pediatric gonadal diseases are genetically and pathologically heterogeneous. Successful management requires not only precise hormonal replacement but also sensitive handling of the profound psychosocial implications of these conditions.

i. The Diagnostic Conundrum of DSD

The diagnostic process for DSD is a time-critical, multi-step challenge, often initiated in the neonatal period by the presence of ambiguous genitalia. The cornerstone of diagnosis involves determining the karyotype, followed by hormonal testing (measuring testosterone, dihydrotestosterone (DHT), cortisol, and precursor steroids like 17-hydroxyprogesterone and molecular genetic analysis (sequencing genes like SRY, AR, and CYP21A2). Pelvic ultrasound or MRI is often used to visualize internal structures (e.g., uterus, cryptorchid testes). The final diagnosis dictates the genetic etiology and, crucially, informs the sex of rearing recommendation—a sensitive decision that must balance biological potential, surgical feasibility, and long-term psychological well-being. Modern consensus advocates for a shift away from rapid, irreversible surgical interventions towards a model based on informed patient/family involvement and multidisciplinary team management.

ii. Hormonal Replacement: Timing and Formulation

Management of primary hypogonadism (e.g., in Turner and Klinefelter syndromes) centers on sex steroid replacement therapy to induce and maintain secondary sexual characteristics and optimize bone health. The timing is critical. Therapy must be initiated at a physiologically appropriate age (typically age 11-12) and started with low, gradually escalating doses ("physiological priming"). This slow titration is essential to mimic the natural progression of puberty, which is crucial for achieving normal growth spurt dynamics and promoting healthy psychosocial development, contrasting sharply with the often high-dose replacement used in adult hypogonadism.

·       In Turner syndrome, estrogen replacement is titrated to achieve optimal bone mineral density and feminization.

·       In Klinefelter syndrome, testosterone replacement is necessary to promote virilization, enhance muscle mass, and address the associated psychological issues (e.g., low self-esteem).

Failure to achieve timely pubertal development leads not only to psychosocial distress but also to increased risk of osteoporosis due to prolonged sex steroid deficiency.

iii. Neoplasia and Surveillance: The Risk of Gonadal Malignancy

The risk of gonadal malignancy is significantly increased in certain DSD conditions, notably those involving Y chromosome material in a dysgenetic gonad (e.g., certain forms of partial Gonadal Dysgenesis or AIS). The presence of the Y chromosome, particularly the SRY gene, in a streak or dysgenetic gonad greatly elevates the risk of gonadoblastoma and subsequent transformation into malignant dysgerminoma or seminoma. Therefore, a central management strategy for high-risk DSDs (such as those with CAIS or Partial Gonadal Dysgenesis reared female) is the prophylactic gonadectomy—the surgical removal of the non-functional, high-risk gonads—often performed after the appropriate age for pubertal induction to minimize hormonal deficiencies prior to replacement. This preventative measure is a major component of reducing long-term morbidity.

iv. The Psychosocial and Ethical Burden

The greatest challenge in managing pediatric gonadal diseases, particularly DSDs, is the psychosocial burden. Conditions involving ambiguous genitalia or non-concordant chromosomal, gonadal, and anatomical sex can lead to parental distress, identity confusion, and psychological morbidity for the child. The management of these disorders is not purely endocrinological or surgical; it is ethically complex, requiring transparent, honest, and sensitive communication by a specialized multidisciplinary team, including medical ethicists and child psychologists. The emphasis must always be on the long-term well-being and autonomy of the child, moving away from past practices that prioritized rapid cosmetic normalization.

Conclusion

Diseases of the sexual glands in children are highly complex disorders rooted in molecular defects that disrupt the critical processes of fetal differentiation and postnatal maturation. The analysis demonstrates a clear pathological segregation: DSDs arise from defects in the SRY pathway or sex steroid synthesis/action during fetal development, Primary Hypogonadism arises from damage (often genetic, as in Turner and Klinefelter syndromes) to the intrinsic gonadal cells postnatally, and Neoplasia (e.g., Granulosa Cell Tumors) disrupts function through autonomous steroidogenesis. The clinical consequences—ranging from ambiguous genitalia and delayed puberty to life-threatening malignancy—necessitate a deeply integrated, multidisciplinary therapeutic approach. The critical elements of successful management include: (1) Precise Genetic Diagnosis to define the malignancy risk; (2) Physiologically Timed Hormone Replacement to induce a healthy pubertal trajectory; and (3) Sensitive Psychosocial Support to address gender identity and long-term reproductive health goals. The contemporary paradigm in pediatric gonadal disease management prioritizes the autonomy of the patient, ensuring all interventions, particularly those that are irreversible, are performed only after careful consideration of the long-term biological, reproductive, and psychological consequences.

References

1.     Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on management of intersex disorders. Arch Dis Child. 2016 Jan;101(1):57-65.

2.     Pasquino AM, Pucarelli I, Segni M, Passeri F, Pedicelli S. Management of Turner Syndrome: A Long-Term Perspective. Horm Res Paediatr. 2017;87(Suppl 1):71–

3.     Cutfield W, Sävendahl L, Foster C. Puberty in boys with Klinefelter syndrome: a prospective international study. J Pediatr. 2020 Jan;216:119–27.

4.     Lange J, Calvo E, Pacaud D, DiVall SA. Pediatric Gonadal Tumors: A Comprehensive Review of Clinical Presentations and Management. Pediatr Clin North Am. 2021 Jun;68(3):497–514.

5.     Flück CE, Güran T, Miller WL. 46, XY DSD: Disorders of androgen synthesis and action. Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101295.

6.     Witchel SF, Azziz R. Management of 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia. Ann Intern Med. 2019 Jun 4;170(11):792–9.

7.     Lee PA, Nordenström A, Houk CP. Terminology and classification of disorders of sex development. J Pediatr Endocrinol Metab. 2017 May 26;30(5):475–83.

8.     Sarafoglou K, Gurnett CA, Popa FJ, Migeon CJ. Adherence to diagnostic and treatment guidelines for congenital adrenal hyperplasia in North America. J Clin Endocrinol Metab. 2018 Jan 1;103(1):210–8.

9.     Wisniewski AB, Migeon CJ, Gearhart JP, Meyer-Bahlburg HF, Money J, Berenbaum SA, et al. Management of children with ambiguous genitalia: a pediatric surgical perspective. J Urol. 2017 Apr;197(4):872–82.

10.  Berglund A, Johannsen TH, Stochholm K, Gravholt CH. Increased mortality in Klinefelter syndrome: a nationwide, population-based cohort study. J Clin Endocrinol Metab. 2018 Mar 1;103(3):888–95.